The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

John R. Tischner, Daniel M. Hartung, Dennis N. Bourdette, Ruth H. Whitham, Brian E. Rittenhouse, Sharia Ahmed

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?'. Together they form a unique fingerprint.